Inflammation modulation

KPV is an investigational peptide, analogue or research construct with evidence ranging from mechanistic studies to limited human trials.

Livagen is an organ-associated short peptide promoted for regulatory or restorative effects, but independent modern clinical evidence is sparse.

Thyreogen is an organ-associated short peptide promoted for regulatory effects, but independent modern clinical evidence is sparse.

Endoluten is an organ-associated short peptide promoted for tissue-specific regulatory effects, but independent modern clinical evidence is sparse.

An endogenous renin-angiotensin-system peptide with vasodilatory, anti-inflammatory and antifibrotic actions in experimental models. Therapeutic administration remains investigational.

Chonluten is an organ-associated short peptide promoted for tissue-specific regulatory effects, but independent modern clinical evidence is sparse.

BPC-157 is an investigational peptide, analogue or research construct with evidence ranging from mechanistic studies to limited human trials.

An investigational erythropoietin-derived peptide studied for neuropathic pain and tissue protection.

Pinealon is an organ-associated short peptide promoted for regulatory effects, but independent modern clinical evidence is sparse.

Bronchogen is an organ-associated short peptide promoted for tissue-specific regulatory effects, but independent modern clinical evidence is sparse.

Cardiogen is an organ-associated short peptide promoted for tissue-specific regulatory effects, but independent modern clinical evidence is sparse.

Cristagen is an organ-associated short peptide promoted for tissue-specific regulatory effects, but independent modern clinical evidence is sparse.

Edp Peptide is an organ-associated short peptide promoted for tissue-specific regulatory effects, but independent modern clinical evidence is sparse.

Ke Peptide is an organ-associated short peptide promoted for regulatory or restorative effects, but independent modern clinical evidence is sparse.

Cibinetide is an investigational peptide, analogue or research construct with evidence ranging from mechanistic studies to limited human trials.

Cartalax is an organ-associated short peptide promoted for tissue-specific regulatory effects, but independent modern clinical evidence is sparse.

Calcitonin is an endogenous peptide with established physiological or receptor-level biology; therapeutic administration and indications are molecule-specific.

Ovagen is an organ-associated short peptide promoted for regulatory or restorative effects, but independent modern clinical evidence is sparse.

Testagen is an organ-associated short peptide promoted for regulatory effects, but independent modern clinical evidence is sparse.

Livatex is an organ-associated short peptide promoted for regulatory or restorative effects, but independent modern clinical evidence is sparse.

Renisamine Peptide is an organ-associated short peptide promoted for regulatory effects, but independent modern clinical evidence is sparse.

Substance P is an endogenous signalling peptide with established or emerging physiological relevance.

Sigumir is an organ-associated short peptide promoted for regulatory effects, but independent modern clinical evidence is sparse.

An endogenous 52-amino-acid peptide hormone involved in vascular tone, endothelial integrity, lymphatic biology and inflammatory responses.